NUCLEIC ACID MOLECULE, POLYPEPTIDE, VECTOR, CELL, IN VITRO METHOD, PHARMACEUTICAL COMPOSITION, USE AND METHOD FOR TREATING CANCER

AR135191A1Pending Publication Date: 2026-07-22FUNDACAO HEMOCENT DE RIBEIRAO PRETO +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: ARP20250100325
Authority / Receiving Office: AR · AR
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-02-07
Filing Date: 2025-02-06
Publication Date: 2026-07-22

Application Information

Patent Timeline

07 Feb 2024

Priority

06 Feb 2025

Application

ARP20250100325

22 Jul 2026

Publication

AR135191A1

IPC: C07K14/705; C07K16/28; C07K16/30; C07K16/46; A61K35/17; A61K39/00; A61K39/395; A61P35/00; A61P35/02; C12N15/09; C12N15/62; C12N15/85; C12N5/0781; C12N5/10

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

No text content released.

Claims

The present invention relates to nucleic acid molecules encoding a chimeric antigen receptor (CAR). The present invention further relates to a chimeric antigen receptor (CAR) polypeptide. The present invention further relates to a vector comprising the nucleic acid molecules defined above. The present invention further relates to a cell expressing the polypeptide defined above. The present invention further relates to an in vitro method for obtaining a cell. The present invention further relates to a pharmaceutical composition comprising the nucleic acid molecule, vector, polypeptides, or cells as defined above and a pharmaceutically acceptable carrier. The present invention further relates to the use of the nucleic acid molecule, vector, polypeptide, or composition as defined above for the treatment of cancer.The present invention further relates to the use of the nucleic acid molecule, vector, polypeptide, or composition as defined above for the production of a medicament for the treatment of cancer. The present invention further relates to a method for treating cancer in a patient.